ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...
Acorda Therapeutics said recently its levodopa inhalation powder for Parkinson disease (PD) has launched in Germany. The product, sold as Inbrija, is commercialized in Germany through an agreement ...
Chance Pharmaceuticals Co. Ltd. acquired greater China rights to Inbrija (levodopa inhalation powder), used to manage Parkinson’s disease (PD), from Acorda Therapeutics Inc. in a deal worth as much as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results